GT Biopharma (GTBP) Return on Capital Employed (2011 - 2026)
GT Biopharma (GTBP) posted quarterly Return on Capital Employed of 201.02% for Q1 2026, down 704299.0% year-over-year from N/an in Q1 2025, and up 36.98% quarter-over-quarter from 318.96% in Q4 2025.
GT Biopharma (GTBP) Return on Capital Employed (2011 - 2026) Analysis & Trends
GT Biopharma (GTBP) has reported Return on Capital Employed for 15 consecutive years, with 201.02% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed fell 704299.0% year-over-year to 201.02%; the TTM figure through Mar 2026 stood at 201.02% (down 704299.0% YoY), while the FY2025 annual figure was 322.65%, up 11682.0% from the prior year.
- Return on Capital Employed advanced to 201.02% in Q1 2026 per GTBP's latest filing, from 318.96% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 6841.97% in Q1 2025 and bottomed at 318.96% in Q4 2025.
- Historically, Return on Capital Employed has averaged 547.33% across 5 years, with a median of 159.8% in 2023.
- Annual changes were most pronounced in 2025 — Return on Capital Employed soared 701742 bps — and 2026, when it sank 704299 bps.
- GT Biopharma's Return on Capital Employed stood at 152.21% in 2022, then decreased by 5 bps to 159.8% in 2023, then jumped by 2311 bps to 3533.58% in 2024, then tumbled by 109 bps to 318.96% in 2025, then surged by 37 bps to 201.02% in 2026.
- Business Quant data shows GTBP's Return on Capital Employed at 201.02% in Q1 2026, 318.96% in Q4 2025, and 240.6% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | GT Biopharma | 8.64 Mn | 8.64 Mn | - | -201.02% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -201.02% |
| Dec 31, 2025 | -318.96% |
| Sep 30, 2025 | -240.60% |
| Jun 30, 2025 | 41.34% |
| Mar 31, 2025 | 6,841.97% |
| Dec 31, 2024 | 3,533.58% |
| Mar 31, 2024 | -175.45% |
| Dec 31, 2023 | -159.80% |
| Sep 30, 2023 | -134.26% |
| Jun 30, 2023 | -140.74% |
| Mar 31, 2023 | -135.89% |
| Dec 31, 2022 | -152.21% |
| Sep 30, 2022 | -191.28% |
| Jun 30, 2022 | -189.53% |
| Mar 31, 2022 | -167.26% |
| Dec 31, 2021 | -242.43% |
| Sep 30, 2021 | -82.94% |
| Jun 30, 2021 | -79.10% |
| Mar 31, 2021 | -162.51% |
| Dec 31, 2020 | -28.00% |